Literature DB >> 11932386

Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus.

Georgia Deliyannis1, David C Jackson, Nicholas J Ede, Weiguang Zeng, Irene Hourdakis, Evaline Sakabetis, Lorena E Brown.   

Abstract

Induction of cytotoxic T-cell-mediated virus-clearing responses by influenza virus T cell determinant-containing peptide immunogens was examined. The most potent synthetic immunogens for eliciting pulmonary viral-clearing responses contained peptides representing determinants for CD4 and CD8 T cells (TH and CTL peptides, respectively) together with two or four palmitic acid (Pal) groups. Inoculated in adjuvant, these Pal2- or Pal4-CTL-TH lipopeptides and the nonlipidated CTL peptide induced equivalent levels of cytolytic activity in the primary effector phase of the response. The ability to recall lytic responses, however, diminished much more rapidly in CTL peptide-primed than in lipopeptide-primed mice. By 15 months postpriming, the recalled lytic activity in lipopeptide-inoculated mice remained potent, but the response induced by the CTL peptide was weak. Enumeration of specific gamma interferon-secreting CD8 T cells revealed that a greater number of these T cells had entered or remained in the memory pool in lipopeptide-primed mice, arguing for a quantitative rather than qualitative enhancement of the response on recall. Addition of either the lipid or the TH peptide to the CTL peptide was not sufficient to provide these long-lived antiviral responses, but inclusion of both components augmented the response. CD4 T cells elicited by the lipopeptides did not influence the rate of viral clearance upon challenge and most likely had a role in induction or maintenance of the memory response. It therefore appears that the lipopeptide immunogens, although not significantly superior at inducing primary effector CD8 T cells, elicit a much more effective memory population, the recall of which may account for their superiority in inducing pulmonary protection after viral challenge.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932386      PMCID: PMC155065          DOI: 10.1128/jvi.76.9.4212-4221.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Extension of HLA-A*0201-restricted minimal epitope by N epsilon-palmitoyl-lysine increases the life span of functional presentation to cytotoxic T cells.

Authors:  E Loing; M Andrieu; K Thiam; D Schörner; K H Wiesmüller; A Hosmalin; G Jung; H Gras-Masse
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

2.  Visualizing the generation of memory CD4 T cells in the whole body.

Authors:  R L Reinhardt; A Khoruts; R Merica; T Zell; M K Jenkins
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

3.  Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class I-restricted CD8(+) T lymphocyte activation.

Authors:  M Andrieu; E Loing; J F Desoutter; F Connan; J Choppin; H Gras-Masse; D Hanau; A Dautry-Varsat; J G Guillet; A Hosmalin
Journal:  Eur J Immunol       Date:  2000-11       Impact factor: 5.532

4.  Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo.

Authors:  P M Taylor; B A Askonas
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

5.  Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).

Authors:  A A Scalzo; S L Elliott; J Cox; J Gardner; D J Moss; A Suhrbier
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

6.  A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells.

Authors:  J D Sedgwick; P G Holt
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

7.  Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens.

Authors:  G A Tannock; J A Paul; R D Barry
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

8.  Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants.

Authors:  M E Andrew; B E Coupar; D B Boyle; G L Ada
Journal:  Scand J Immunol       Date:  1987-01       Impact factor: 3.487

10.  Disquisitions of Original Antigenic Sin. I. Evidence in man.

Authors:  R G Webster
Journal:  J Exp Med       Date:  1966-09-01       Impact factor: 14.307

View more
  27 in total

1.  Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.

Authors:  Tze Guan Tan; Ernest Mui; Hua Cong; William H Witola; Alexandre Montpetit; Stephen P Muench; John Sidney; Jeff Alexander; Alessandro Sette; Michael E Grigg; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-03-26       Impact factor: 3.641

2.  The magnitude of local immunity in the lungs of mice induced by live attenuated influenza vaccines is determined by local viral replication and induction of cytokines.

Authors:  Yuk-Fai Lau; Celia Santos; Fernando J Torres-Vélez; Kanta Subbarao
Journal:  J Virol       Date:  2010-10-20       Impact factor: 5.103

3.  A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.

Authors:  David C Jackson; Yuk Fai Lau; Thuy Le; Andreas Suhrbier; Georgia Deliyannis; Christina Cheers; Corey Smith; Weiguang Zeng; Lorena E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

4.  B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms.

Authors:  Javier Rangel-Moreno; Damian M Carragher; Ravi S Misra; Kim Kusser; Louise Hartson; Amy Moquin; Frances E Lund; Troy D Randall
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

5.  DNA-epitope vaccine provided efficient protection to mice against lethal dose of influenza A virus H1N1.

Authors:  Huiling Wei; Stephen D Lenz; David H Thompson; Roman M Pogranichniy
Journal:  Viral Immunol       Date:  2014-01-09       Impact factor: 2.257

Review 6.  Influenza, immune system, and pregnancy.

Authors:  Renju S Raj; Elizabeth A Bonney; Mark Phillippe
Journal:  Reprod Sci       Date:  2014-06-04       Impact factor: 3.060

7.  Highly conserved hemagglutinin peptides of H1N1 influenza virus elicit immune response.

Authors:  Neha Lohia; Manoj Baranwal
Journal:  3 Biotech       Date:  2018-11-20       Impact factor: 2.406

8.  A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection.

Authors:  Brendon Y Chua; Emily M Eriksson; Lorena E Brown; Weiguang Zeng; Eric J Gowans; Joseph Torresi; David C Jackson
Journal:  Vaccine       Date:  2008-04-07       Impact factor: 3.641

9.  Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity.

Authors:  Olivier Renaudet; Gargi Dasgupta; Ilham Bettahi; Alda Shi; Anthony B Nesburn; Pascal Dumy; Lbachir BenMohamed
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

10.  Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii.

Authors:  Hua Cong; Ernest J Mui; William H Witola; John Sidney; Jeff Alexander; Alessandro Sette; Ajesh Maewal; Rima McLeod
Journal:  Immunome Res       Date:  2010-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.